Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15259
UPID:
NPHP1_HUMAN
Alternative names:
Juvenile nephronophthisis 1 protein
Alternative UPACC:
O15259; O14837
Background:
Nephrocystin-1, also known as Juvenile nephronophthisis 1 protein, plays a crucial role in kidney cell organization, retina development, and spermatogenesis. It is involved in epithelial cell polarity, apical junction organization, and intraflagellar transport during cilia assembly, influencing the movement of IFT proteins such as IFT88 and WDR19.
Therapeutic significance:
Nephrocystin-1 is implicated in several genetic disorders, including Nephronophthisis 1, Senior-Loken syndrome 1, and Joubert syndrome 4. These diseases highlight the protein's critical role in kidney and eye health, underscoring the importance of targeting Nephrocystin-1 in therapeutic strategies for renal-retinal syndromes.